Alyssa Wyant joined EryDel S.p.A. as Senior Vice President, Regulatory Affairs in January 2019. Alyssa has over 20 years of global regulatory experience with a focus on the development, registration and successful launches of innovative, biologic and small molecule orphan disease products. Prior to joining EryDel, Alyssa served on the management team at Edge Therapeutics from 2017 to 2018 as Senior Vice President, Regulatory Affairs, where she was responsible for the development of a treatment for aneurysmal subarachnoid hemorrhage. Previous positions included serving as Vice President, Global Regulatory Affairs at PTC Therapeutics from 2015 to 2017, where she oversaw the international regulatory activities for a product treating several orphan disease indications, including Duchenne muscular dystrophy and cystic fibrosis. As Senior Director, International Regulatory Affairs at NPS Pharmaceuticals from 2012 to 2015, she supported FDA approval for an orphan product for hypoparathyroidism, and oversaw the U.S. and EU launches of another orphan product for short bowel syndrome. Alyssa also held multiple leadership positions in global regulatory affairs over a 9-year period at Shire Human Genetic Therapies in the U.S. and Switzerland, where she was a key contributor in obtaining, maintaining, and extending registration of 3 enzyme replacement therapies for orphan diseases. Ms. Wyant has a B.S. in cell and molecular biology from the University of Washington.